Library — CHDR

Search

Filter

Using machine learning techniques to characterize sleep-deprived driving behavior.

van der Wall HEC, Doll RJ, van Westen GJP, Koopmans I, Zuiker RG, Burggraaf J, Cohen AF

Traffic injury prevention, 2021 May

View publication
PK/PD modeling of 5-hydroxytryptophan (5-HTP) challenge test with cortisol measurement in serum and saliva.

Guan Z, Jacobs G, van Pelt H, Van Gerven JMA, Burggraaf J, Zhao W

Pharmacology research & perspectives, 2020 Mar; 8(2):e00574

View publication
Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration.

Muehlan C, Boehler M, Brooks S, Zuiker R, van Gerven J, Dingemanse J

Journal of psychopharmacology (Oxford, England), 2020 Mar

View publication
The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder

Kasper Recourt, Peter de Boer, Rob Zuiker, Remy Luthringer, Justine Kent, Peter van der Ark, Ilse Van Hove, Joop van Gerven, Gabriel Jacobs, Luc van Nueten and Wayne Drevets

2019 Sep

View publication
Metabolism of the Dual Orexin Receptor Antagonist ACT-541468, Based on Microtracer/ Accelerator Mass Spectrometry.

Muehlan C, Fischer H, Zimmer D, Aissaoui H, Grimont J, Boss C, Croft M, van Gerven J, Krähenbühl S, Dingemanse J

Current drug metabolism, 2019 Jul; 20(4):254-265

View publication
Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration.

Muehlan C, Brooks S, Zuiker R, van Gerven J, Dingemanse J

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2019 Jul; 29(7):847-857

View publication
Central nervous system effects of the histamine-3 receptor antagonist CEP-26401, in comparison with modafinil and donepezil, after a single dose in a cross-over study in healthy volunteers.

Baakman AC, Zuiker R, van Gerven JMA, Gross N, Yang R, Fetell M, Gershon A, Gilgun-Sherki Y, Hellriegel E, Spiegelstein O

British journal of clinical pharmacology, 2019 Mar

View publication
A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity.

De Boer P, Drevets WC, Rofael H, van der Ark P, Kent JM, Kezic I, Parapatics S, Dorffner G, van Gerven J, Beneš H, Keicher C, Jahn H, Seiden DJ, Luthringer R

Journal of psychopharmacology (Oxford, England), 2018 Dec; 32(6):668-677

View publication
Accelerated development of the dual orexin receptor antagonist ACT-541468: Integration of a microtracer in the first-in-human study.

Muehlan C, Heuberger J, Juif PE, Croft M, van Gerven J, Dingemanse J

Clinical pharmacology and therapeutics, 2018 May

View publication

«
1
2
3
»